Market Take: Boston Life Sciences Real Estate Shows Improving Momentum

Greater Boston remains one of the most important life sciences clusters in the world. Its concentration of pharmaceutical and biotechnology companies, research institutions, hospitals, universities, and skilled workers continues to make the region a major destination for the industry.

The real estate market supporting that ecosystem, however, is still correcting after several years of rapid development and slower leasing activity.

According to David Thomann of Cushman & Wakefield, the U.S. life sciences real estate market showed improving momentum during the first quarter of 2026. Stronger funding, robust M&A and licensing activity, and continued pharmaceutical investment in research, development, and manufacturing all contributed to a more constructive outlook.

Demand remained stable, vacancy growth slowed, and new construction shifted further toward build-to-suit projects rather than speculative development. Venture capital funding increased approximately 15% year over year, IPO activity strengthened, and investor interest remained strong despite a modest decline in property sales.

For Greater Boston, those trends are beginning to show up through major leasing decisions and new facility commitments.

Greater Boston’s life sciences real estate market totals approximately 50.3 million square feet.

At the end of 2025, vacancy stood at 34%, up 500 basis points from the prior year. Supply and demand remained largely unbalanced, and only 18% of the nearly 2 million square feet of new inventory delivered during the year had been leased.

The construction pipeline remains substantial, but the market has begun to adjust. Groundbreakings have slowed, and developers are increasingly prioritizing projects backed by committed tenants instead of relying on speculative leasing demand.

Despite those challenges, leasing activity improved during 2025. Annual demand reached 2.1 million square feet, an increase of 72.2% from the prior year. Cambridge accounted for more than half of all market activity.

That does not mean the vacancy problem has been resolved. It does suggest that the market is beginning to stabilize.

One of the strongest recent signals came from Sanofi.

The company renewed and expanded its commitment to its Cambridge Crossing headquarters, extending leases covering approximately 900,000 square feet across two buildings. The transaction is one of the largest office and laboratory renewal deals in Massachusetts history.

For a real estate market dealing with high vacancy and oversupply, a commitment of that size is significant.

Sanofi’s decision comes alongside activity from companies including AvenCell, Zealand Pharma, Lila Sciences, and TransMedics. Together, those commitments signal improving confidence and momentum within Greater Boston’s biotech and life sciences property market.

Sanofi’s 900,000-Square-Foot Commitment to Boston Life Sciences Real Estate

In the accompanying Market Take, Thomann explains why the Cambridge Crossing renewal matters for a market still working through excess supply and elevated vacancy.

Another notable development is AdvanCell’s decision to establish its U.S. global headquarters in Greater Boston.

The radiopharmaceutical company secured an approximately 130,000-square-foot facility in Andover that will serve as its flagship U.S. center. The location will support the development and future commercialization of the company’s targeted therapy pipeline while complementing its established research, development, and manufacturing capabilities in Australia.

From a commercial real estate perspective, the decision is especially notable because Greater Boston has historically attracted pharmaceutical research and development operations more consistently than large-scale manufacturing facilities.

Many pharmaceutical companies have maintained R&D centers in the region while placing manufacturing operations in markets such as Research Triangle Park, the Midwest, or other lower-cost locations.

AdvanCell’s commitment adds to the growing momentum around pharmaceutical manufacturing in Greater Boston and broadens the types of life sciences facilities being established in the market.

Boston and Cambridge continue to rank among the leading U.S. markets for life sciences talent, alongside the Bay Area, San Diego, and Raleigh-Durham.

Greater Boston has approximately 109,400 life sciences workers, and sector employment has grown 94.7% over the past decade.

The region also benefits from a strong education pipeline. Life sciences degree completions increased from 5,437 in 2014 to 7,236 in 2024, a gain of 33%.

Major research institutions continue to support the market as well. Massachusetts General Hospital, Brigham and Women’s Hospital, and Boston Children’s Hospital received a combined total of approximately $3.9 billion in National Institutes of Health funding between 2023 and 2025.

That concentration of talent and research infrastructure remains one of Greater Boston’s strongest competitive advantages.

Cost remains a challenge. Thomann noted that wage pressure and the broader cost of living continue to differentiate markets. Chicago and Denver-Boulder, for example, offer compelling labor and cost advantages for companies considering expansion.

Boston’s talent base remains deep, but companies will continue weighing access to that talent against the cost of operating in the region.

Trade policy and tariffs remain another source of uncertainty for commercial real estate construction.

Although some tariff pressure has eased, Thomann said pricing has reset at a permanently higher level. Builders, contractors, developers, and end users are still absorbing increased material costs, making new developments more difficult to underwrite.

The current environment favors well-capitalized sponsors with the ability to absorb higher costs and adjust to longer timelines.

Developers will also need to revise return expectations and project feasibility assumptions as the market adapts to the higher-cost environment.

With additional changes to trade policy still possible, monitoring tariffs, import activity, and construction costs will remain critical to managing risk and maintaining project viability.

Greater Boston’s life sciences ecosystem remains one of the strongest in the country. The challenge is not a lack of scientific talent, research activity, or industry importance. The challenge is an, research activity, or industry importance. The challenge is an overbuilt real estate market that is still working through excess supply.

The latest activity offers reasons for measured optimism.

Sanofi has committed to approximately 900,000 square feet in Cambridge. AdvanCell is establishing a major manufacturing operation in Andover. Venture funding increased year over year, IPO activity strengthened, and vacancy growth slowed.

None of that represents a full recovery.

It does show that Greater Boston’s life sciences real estate market is beginning to regain momentum.